RARE DISEASE
Epidermolysis bullosa acquisita
Epidermolysis bullosa acquisita
Epidermolysis bullosa acquisita
Synonyms: Acquired epidermolysis bullosa
Synonyms: Acquired epidermolysis bullosa
Synonyms: Acquired epidermolysis bullosa
Drug discovery
1
drug
With orphan designation
Overview
Epidermolysis bullosa acquisita (EBA) is a rare, chronic autoimmune subepidermal blistering disorder caused by IgG autoantibodies targeting type VII collagen, a critical component of dermal-epidermal anchoring fibrils. It manifests as trauma-induced blisters, mucosal involvement, and healing with scarring/milia. Diagnosis requires skin biopsy with direct immunofluorescence and salt-split indirect immunofluorescence. Treatment combines immunosuppression with meticulous wound care, but disease control remains challenging due to frequent resistance to therapy [1][2][7][12].
Population
Incidence: 0.08–0.5 cases/million/year, with higher rates in Germany (2.8/million) [2][12]
Onset: Bimodal peaks in early adulthood (20–30s) and later decades (50–70s); 5% pediatric cases [6][7][12]
Associations: Systemic lupus erythematosus, inflammatory bowel disease, and lichen planus (HR 3.1–26.9) [4][7][14]
Burden
Morbidity: Chronic scarring, nail dystrophy, ocular/corrosive mucosal lesions (50–65% of cases), and sepsis risk (HR 1.94) [4][7][12][14]
Cancer risk: 2.5× higher mortality vs. general population; squamous cell carcinoma in chronic lesions [4][9][12]
Quality of life: Severe pain, pruritus, and financial strain from wound care costs (~$20k/month in severe cases) [5][10][20]
Therapies
First-line: Systemic corticosteroids (0.5–2 mg/kg/day) ± dapsone or colchicine [1][2][7]
Refractory disease: Rituximab, IV immunoglobulin (IVIG), immunoadsorption, or cyclosporine; combination therapies show superior remission rates [3][8][14][18]
Supportive care: Infection prevention, non-adherent dressings, and nutritional support for mucosal lesions [6][10][12]
Categories: rare skin diseases
Research Papers
369 drug discovery papers about Epidermolysis bullosa acquisita, with 2 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
369 drug discovery papers about Epidermolysis bullosa acquisita, with 2 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-05-08 | HLA genotype, clinical and immunofluorescence findings of 30 patients with type VII collagen antibody positive subepidermal bullous disease.
Epidermolysis bullosa acquisita (EBA) and mucous membrane pemphigoid are mucocutaneous blistering disorders that are associated with antibodies that target type VII collagen (anti-col7). There are relatively few studies that closely investigate the clinical phenotype and HLA genotype of patients who are anti-col7 positive. We therefore characterized all patients with anti-col7-positive subepidermal bullous disease that were treated at our centre. In total, 30 patients were identified, 29 had mechanobullous skin lesions and all had oral ulceration. The most common sites for oral lesions were the tongue, lip and palatal mucosa. Laryngeal and oesophageal lesions were seen in five and six patients, respectively. Oesophageal involvement was associated with erosions and stricture formation in the cervical or thoracic oesophagus and the majority of patients with oesophageal involvement had concomitant bullous pemphigoid180/230 antibodies and were of Black African ancestry. IgA deposition on direct immunofluorescence was associated with lower age at disease onset but did not correlate with clinical features or autoantibody profiles. Concomitant BP180/230 antibody positivity was associated with earlier disease onset and Black African ancestry. HLA genotyping was performed in 18 patients and demonstrated HLA-DQB1*03 and HLA-DQB1*06 alleles were most commonly associated with anti-col7 EBA. HLA genotype did not, however, correlate with clinical features of autoantibody profiles. Taken together, this study demonstrates that concomitant BP180/230 and anti-col7 antibodies are associated with earlier disease onset, Black African ancestry and potentially oesophageal involvement.
2026-03-30 | Tyrosine kinase signaling pathways as therapeutic targets in autoimmune subepidermal blistering skin diseases (pemphigoid diseases).
Pemphigoid diseases, such as bullous pemphigoid and epidermolysis bullosa acquisita, are severe organ-specific autoimmune diseases characterized by subepidermal skin blistering with increasing incidence in recent years. Although there have been substantial advances in understanding the pathomechanism of these diseases in the last decades, and the first specific therapy targeting the IL-4 and IL-13 pathway (dupilumab) has been approved by the FDA for bullous pemphigoid, further research is needed to eventually improve patient care. The characteristics of pemphigoid diseases include the formation of immune complexes and their recognition by Fcγ-receptors, as well as the development of a characteristic inflammatory cytokine microenvironment in the skin of the affected patients. Several non-receptor tyrosine kinases are involved in these events, playing a very important role in various signaling processes of immune cells. While certain Src-family kinases and the Syk tyrosine kinase play a very important role in signaling by Fcγ-receptors, JAK-family kinases are crucial players in the signaling of various cytokine receptors including, among others, the receptors of IL-4 and IL-13. The inhibition of these tyrosine kinases with small molecule inhibitors is an emerging therapeutic option in the treatment of an increasing number of immune-mediated diseases. Moreover, numerous studies have been conducted to examine proteins (including PLCγ2 and CARD9) in signal transduction following Fcγ-receptor activation in in vitro and in vivo experimental pemphigoid models, and an increasing number of case studies involving JAK inhibitors report the successful application of these drugs in various pemphigoid diseases. This review summarizes our current understanding of the therapeutically most promising tyrosine kinase signaling pathways in the pathogenesis of pemphigoid diseases.
2026-03-28 | Autoimmune Bullous Dermatoses in Adults: A Clinical, Histopathological, and Immunological Differential Diagnostic Approach
Autoimmune bullous dermatoses are a heterogeneous group of rare, immune-mediated disorders characterized by blister formation affecting the skin and, in many cases, mucous membranes. These diseases arise from autoantibodies directed against specific structural proteins within the epidermis or at the dermoepidermal junction, leading to loss of tissue integrity and clinically distinct blistering patterns. The pathogenic mechanisms underlying these conditions determine their classification into intraepidermal disorders, such as pemphigus vulgaris and pemphigus foliaceus, and subepidermal disorders, including bullous pemphigoid, mucous membrane pemphigoid, linear IgA bullous dermatosis, dermatitis herpetiformis, and epidermolysis bullosa acquisita. Each entity is defined by characteristic autoantigens, immunopathological features, and clinical behavior. Accurate diagnosis represents a major clinical challenge due to overlapping presentations and variable disease severity. A structured diagnostic approach integrating clinical evaluation, histopathological analysis, and immunological testing is therefore essential. Histopathology allows determination of the level of blister formation and inflammatory patterns, while direct immunofluorescence remains the diagnostic gold standard by demonstrating disease-specific deposition of immunoglobulins and complement components. Indirect immunofluorescence and serological assays further refine diagnosis by identifying circulating autoantibodies and their antigenic targets, supporting precise disease classification. Special clinical scenarios, including drug-induced forms, paraneoplastic associations, elderly patients with atypical presentations, and overlap syndromes, add further complexity and underscore the need for heightened diagnostic awareness. Precise diagnosis has direct therapeutic and prognostic implications, as treatment strategies and expected outcomes are closely linked to the underlying immunological profile. An integrated, multidisciplinary diagnostic framework is therefore critical for optimizing treatment selection, guiding long-term management, and improving outcomes in adults with autoimmune bullous dermatoses.
2026-05-08 | HLA genotype, clinical and immunofluorescence findings of 30 patients with type VII collagen antibody positive subepidermal bullous disease.
Epidermolysis bullosa acquisita (EBA) and mucous membrane pemphigoid are mucocutaneous blistering disorders that are associated with antibodies that target type VII collagen (anti-col7). There are relatively few studies that closely investigate the clinical phenotype and HLA genotype of patients who are anti-col7 positive. We therefore characterized all patients with anti-col7-positive subepidermal bullous disease that were treated at our centre. In total, 30 patients were identified, 29 had mechanobullous skin lesions and all had oral ulceration. The most common sites for oral lesions were the tongue, lip and palatal mucosa. Laryngeal and oesophageal lesions were seen in five and six patients, respectively. Oesophageal involvement was associated with erosions and stricture formation in the cervical or thoracic oesophagus and the majority of patients with oesophageal involvement had concomitant bullous pemphigoid180/230 antibodies and were of Black African ancestry. IgA deposition on direct immunofluorescence was associated with lower age at disease onset but did not correlate with clinical features or autoantibody profiles. Concomitant BP180/230 antibody positivity was associated with earlier disease onset and Black African ancestry. HLA genotyping was performed in 18 patients and demonstrated HLA-DQB1*03 and HLA-DQB1*06 alleles were most commonly associated with anti-col7 EBA. HLA genotype did not, however, correlate with clinical features of autoantibody profiles. Taken together, this study demonstrates that concomitant BP180/230 and anti-col7 antibodies are associated with earlier disease onset, Black African ancestry and potentially oesophageal involvement.
2026-03-30 | Tyrosine kinase signaling pathways as therapeutic targets in autoimmune subepidermal blistering skin diseases (pemphigoid diseases).
Pemphigoid diseases, such as bullous pemphigoid and epidermolysis bullosa acquisita, are severe organ-specific autoimmune diseases characterized by subepidermal skin blistering with increasing incidence in recent years. Although there have been substantial advances in understanding the pathomechanism of these diseases in the last decades, and the first specific therapy targeting the IL-4 and IL-13 pathway (dupilumab) has been approved by the FDA for bullous pemphigoid, further research is needed to eventually improve patient care. The characteristics of pemphigoid diseases include the formation of immune complexes and their recognition by Fcγ-receptors, as well as the development of a characteristic inflammatory cytokine microenvironment in the skin of the affected patients. Several non-receptor tyrosine kinases are involved in these events, playing a very important role in various signaling processes of immune cells. While certain Src-family kinases and the Syk tyrosine kinase play a very important role in signaling by Fcγ-receptors, JAK-family kinases are crucial players in the signaling of various cytokine receptors including, among others, the receptors of IL-4 and IL-13. The inhibition of these tyrosine kinases with small molecule inhibitors is an emerging therapeutic option in the treatment of an increasing number of immune-mediated diseases. Moreover, numerous studies have been conducted to examine proteins (including PLCγ2 and CARD9) in signal transduction following Fcγ-receptor activation in in vitro and in vivo experimental pemphigoid models, and an increasing number of case studies involving JAK inhibitors report the successful application of these drugs in various pemphigoid diseases. This review summarizes our current understanding of the therapeutically most promising tyrosine kinase signaling pathways in the pathogenesis of pemphigoid diseases.
2026-03-28 | Autoimmune Bullous Dermatoses in Adults: A Clinical, Histopathological, and Immunological Differential Diagnostic Approach
Autoimmune bullous dermatoses are a heterogeneous group of rare, immune-mediated disorders characterized by blister formation affecting the skin and, in many cases, mucous membranes. These diseases arise from autoantibodies directed against specific structural proteins within the epidermis or at the dermoepidermal junction, leading to loss of tissue integrity and clinically distinct blistering patterns. The pathogenic mechanisms underlying these conditions determine their classification into intraepidermal disorders, such as pemphigus vulgaris and pemphigus foliaceus, and subepidermal disorders, including bullous pemphigoid, mucous membrane pemphigoid, linear IgA bullous dermatosis, dermatitis herpetiformis, and epidermolysis bullosa acquisita. Each entity is defined by characteristic autoantigens, immunopathological features, and clinical behavior. Accurate diagnosis represents a major clinical challenge due to overlapping presentations and variable disease severity. A structured diagnostic approach integrating clinical evaluation, histopathological analysis, and immunological testing is therefore essential. Histopathology allows determination of the level of blister formation and inflammatory patterns, while direct immunofluorescence remains the diagnostic gold standard by demonstrating disease-specific deposition of immunoglobulins and complement components. Indirect immunofluorescence and serological assays further refine diagnosis by identifying circulating autoantibodies and their antigenic targets, supporting precise disease classification. Special clinical scenarios, including drug-induced forms, paraneoplastic associations, elderly patients with atypical presentations, and overlap syndromes, add further complexity and underscore the need for heightened diagnostic awareness. Precise diagnosis has direct therapeutic and prognostic implications, as treatment strategies and expected outcomes are closely linked to the underlying immunological profile. An integrated, multidisciplinary diagnostic framework is therefore critical for optimizing treatment selection, guiding long-term management, and improving outcomes in adults with autoimmune bullous dermatoses.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Epidermolysis bullosa acquisita.
1 orphan drug designation for Epidermolysis bullosa acquisita.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile | small molecules | FDA | 2017-01-05 | — | Almirall, S.A. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.